### Analysis:

Johnson & Johnson's earnings call for the second quarter of 2011 highlighted several key points that should impact the stock price over the next 1–2 weeks:

1. **Operational Performance**: The company reported solid operational growth, particularly in the medical devices and diagnostics segment, which grew 1.3% operationally. This growth was driven by strong results in key franchises like Ethicon and DePuy.

2. **Guidance**: The company maintained its guidance for 2011, expecting sales growth of 2.5% to 3.5% and EPS growth of 3% to 5%. This indicates confidence in the company's ability to sustain growth despite challenging market conditions.

3. **Product Launches**: There were several notable product launches, such as the new energy generator and the GLOSAIR healthcare environmental decontamination system, which are expected to drive growth in the future.

4. **Strategic Decisions**: The company announced plans to restructure the Cordis business to focus on other cardiovascular therapies and to divest certain businesses. These strategic decisions indicate a focus on long-term growth and diversification.

5. **Integration with Synthese**: The acquisition of Synthese is expected to close in the first half of 2012, and integration planning is well underway. This acquisition will strengthen the company's position in the orthopedics market.

### Conclusion:

Given the strong operational performance, the maintenance of guidance, and the strategic decisions to focus on growth areas, the stock is likely to see positive momentum in the short term. The company's ability to navigate challenging market conditions and continue to launch innovative products suggests that the stock will likely rally over the next 1–2 weeks.

**Rating:** 2